apigenin

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: apigenin
• 英文别名: 6,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one；6,7,4'-Trihydroxyflavone；6,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one
• 化学式: C₁₅H₁₀O₅
• 分子量: 270.241
• InChiKey: XADJWCRESPGUTB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  87
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 氢溴酸 、 溶剂黄146 作用下， 生成 apigenin
  参考文献：
  名称：

  Bargellini; Grippa, Gazzetta Chimica Italiana, 1927, vol. 57, p. 607

  摘要：

  DOI：

文献信息

• Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases
  申请人：Gong Qiang Bang

  公开号：US20050049206A1

  公开（公告）日：2005-03-03

  In this invention, we describe a group of flavonoids and flavonoid-containing extracts that have pharmaceutical properties which are useful in the medicinal therapy of fibrotic diseases for the treatment or reparation and prevention of fibrotic lesional tissues. Representative flavonoids and flavonoid-containing extracts have the active compositions of the below formula. Those compositions can be extracted and purified from the botanicals, including Scutellaria baicalensis Georgi, Scutellaria scordifolia Fisch,Oroxylum indicum(L.) Vent, Plantago major L. The compositions of the invention are novel as an anti-fibrotic drugs, as agents for treating fibrosis.

  在这项发明中，我们描述了一组黄酮类化合物和含黄酮类化合物的提取物，具有药物特性，可用于治疗纤维化疾病的药物疗法，用于治疗、修复和预防纤维化病变组织。代表性的黄酮类化合物和含黄酮类化合物的提取物具有以下公式的活性成分。这些成分可以从植物中提取和纯化，包括黄芩、紫花地丁、橙黄木、车前草等。本发明的成分作为抗纤维化药物和治疗纤维化的药剂是新颖的。
• METABOLIC ENGINEERING FOR PLANT DISEASE RESISTANCE
  申请人：Li Wensheng

  公开号：US20100319084A1

  公开（公告）日：2010-12-16

  The invention provides methods and compositions for making a dicotyledonous plant that is susceptible to Phymatotrichopsis Root Rot (PRR) more resistant to PRR, by metabolic engineering of the plant's flavonoid and isoflavonoid biosynthetic pathways. Thus, methods for increasing the synthesis and accumulation of medicarpin and/or 7,4′-dihydroxyflavone in plants such as alfalfa are provided.
• US9238821B2
  申请人：——

  公开号：US9238821B2

  公开（公告）日：2016-01-19
• [EN] COMPOSITIONS OF FLAVONOIDS AND FLAVONOID-CONTAINING EXTRACTS AND THE TREATMENT OF DISEASES<br/>[FR] COMPOSITIONS DE FLAVONOIDES ET D'EXTRAITS QUI CONTIENNENT DES FLAVONOIDES, ET TRAITEMENT DE MALADIES
  申请人：SHANGHAI COMMAN PHARMACEUTICAL

  公开号：WO2005020881A2

  公开（公告）日：2005-03-10

  In this invention we describe a group of flavonoids and flavonoid-containing extracts that have pharmaceutical properties which are useful in the medicinal therapy of fibrotic diseases for the treatment or reparation and prevention of fibrotic lesional tissues. Representative flavonoids and flavonoid-containing extracts have the active compositions of the below formula (I). Those compositions can be extracted and purified from the botanicals, including Scutellaria baicalensis Georgi, Scutellaria scordifolia Fish, Oroxylum indicum (L.) Vent, Plantago major L. The compositions of the invention are novel as an anti-fibrotic drugs, as agents for treating fibrosis.
• [EN] CCR5 RECEPTOR ANTAGONIST MOLECULES<br/>[FR] MOLECULES ANTAGONISTES DU RECEPTEUR CCR5
  申请人：AVANCE PHARMA INC

  公开号：WO2007038875A1

  公开（公告）日：2007-04-12

  [EN] The invention is directed to komaroviquinone, compound 1, 4 rings, heterocyclic (6,5,6,6-ring system), as CCR5 receptor antagonist, and to a pharmaceutical formulation comprising compound 1. The invention further relates to a use of the pharmaceutical composition comprising CCR5 receptor antagonist compound 1 alone or with one or more antiviral agents or other agents in the treatment of HIV-1.
  [FR] L'invention concerne la komaroviquinone, composé 1 à 4 noyaux, hétérocyclique (système à 6,5,6,6 noyaux), en tant qu'antagoniste du récepteur CCR5, ainsi qu'une formulation pharmaceutique contenant le composé 1. La présente invention porte également sur l'utilisation d'une composition pharmaceutique contenant le composé 1 antagoniste du récepteur CCR5, seul ou avec un ou plusieurs agents antiviraux pour le traitement du VIH 1.